Introduction {#s001}
============

Worldwide, the burden of adverse health conditions is substantial among transgender women and travestis (trans women)---people who were assigned as male at birth but identify themselves as females.^[@B1]^ Notwithstanding, they are an underserved group, with several gaps in knowledge regarding their health.^[@B2]^ Although there is no definitive definition, the term travesti has historical and political significance in Brazil and is mostly used to refer to people of the feminine spectrum that, in general, do not wish to undergo reassignment.^[@B5]^

Estimates showed that the transgender population size is small, ranging from 0.5% to 0.9% of the overall population^[@B3]^ but, nevertheless, has a disproportionate HIV risk.^[@B1]^ A systematic review, using data from 2000 to 2011, found that HIV prevalence reached 18% in this population, with a 50-fold increased odds of infection compared with other adults in the reproductive age.^[@B6]^ Some of the highest HIV prevalence rates occur in Latin America, where trans women live in the context of profound social exclusion and is a population most vulnerable to HIV.^[@B7]^ This vulnerability is a result of the complex interactions of risks at the individual level (condomless anal sex, substance use, sex work), interpersonal risks (high-risk partner pool), and structural factors (social exclusion, violence, discrimination, unemployment).^[@B8],[@B9]^ Recent data showed a high HIV prevalence in this population in 12 Brazilian cities.^[@B10]^ One study recently reported 31.2% HIV prevalence among trans women in Rio de Janeiro, Brazil.^[@B11]^

Although trans women are a key population for HIV infection, there are very few tailored prevention and treatment programmes and interventions specifically designed for this population. Historically, trans women were inappropriately grouped with men who have sex with men, which not only hindered the attainment of trans-specific data but also limited their visibility in research and surveillance studies.^[@B2],[@B12]^ Surveillance systems do not usually identify transgender respondents, and scientific data are still scarce, with a dearth of longitudinal data.^[@B2]^ To fill this gap, we established the Oswaldo Cruz Foundation (Fiocruz) Transgender Health Clinical Cohort (Transcendendo) with the primary aim of studying the health outcomes in trans women living in Rio de Janeiro, Brazil. We here describe cohort procedures in addition to trans women baseline characteristics.

Methods {#s002}
=======

Ethic statement {#s003}
---------------

The study was reviewed and approved by the Evandro Chagas National Institute of Infectious Diseases ethics review board at Fiocruz. All information was de-identified before analysis. All participants signed an informed consent form before study procedures. The files have highly restricted access by any personnel.

Study population {#s004}
----------------

Transcendendo is a prospective, open, clinic-based cohort, established in August 2015, to longitudinally evaluate health outcomes among trans women. Inclusion criteria are: ≥18 years of age and self-reported gender identity different from male sex assigned at birth. We present the baseline data of participants enrolled from August 2015 to July 2017.

Study participants were derived from three sources, as shown in [Figure 1](#f1){ref-type="fig"}: (1) referral from Transcender, a respondent-driven sampling (RDS) study conducted at our clinic in Fiocruz,^[@B11]^ (2) trans women who reached the site seeking participation in other studies or HIV prevention or care, and (3) from the Fiocruz HIV Clinical Cohort, described elsewhere.^[@B13]^

![Transcendendo participant flowchart, Rio de Janeiro, Brazil, 2015--2017.](fig-1){#f1}

Trans women are a vulnerable population hardly accessible by classic sampling frame techniques for multiple reasons.^[@B14]^ A useful nonprobabilistic methodology for these populations is RDS, which is a chain referral method of recruitment. We employed RDS to recruit 345 trans women to Transcender from August 2015 to January 2016, 271 (78.5%) of whom were enrolled in Transcendendo. Every participant from Transcender had an initial visit scheduled for Transcendendo, but 74 (21.5%) did not return to the appointment (21 were not reachable with the contact information provided, 3 were no longer living in Rio de Janeiro, 14 declined to participate, and 36 were rescheduled for a second appointment but never returned).

After Transcender\'s closure, inclusion into our cohort was modified to any trans woman who spontaneously sought medical HIV care or prevention at our clinic. During the period from February 2016 to July 2017, 37 trans women reached our services and were enrolled in the cohort. Additionally, during this period, we reviewed the electronic records of patients from the Fiocruz HIV Clinical Cohort to identify potential candidates, which we defined as participants who were assigned as male at birth and had any mention of the term "trans" or social names in their files. This review process identified 70 trans women: as of July 2016, 12 are deceased, 15 were lost to follow-up, and 34 were potential participants. We tried to invite these 34 participants to join the cohort; 14 got enrolled as of July 2017. For the remaining 20 participants, although we tried to contact them, we hardly had any success.

To improve trans women engagement and retention, our setting presented itself as a welcoming, gender-affirming environment by using preferred names and pronouns; respecting gender identities, diversity, and expressions; providing safe, gender-neutral toilets; publicizing trans-affirming posters; offering continuous staff training on gender issues; and enabling friendly interactions between trans women and site staff. Finally, we established partnerships to facilitate social demands, such as adjustment of names in the documents, legal assistance, and providing access to potential interventions that could reduce stigma and socioeconomic disparities.

Study procedures {#s005}
----------------

### Measures {#s006}

Study visits occur on an annual basis ([Table 1](#T1){ref-type="table"}). Each of these visits comprises face-to-face interviews using structured questionnaires, performed by trained professionals (∼90 min), to collect detailed data on sociodemographics, sexual behavior, gender affirmation procedures, hormone and antiretroviral use (for HIV prevention or treatment), discrimination and violence, alcohol, tobacco, and drug use, physical and mental health, history of sexually transmitted infections (STIs), HIV testing history, HIV prevention, and HIV care information (for those HIV-infected).

###### 

Study Procedures: Transcendendo Cohort

  Study procedures                                                                               Entry evaluation   Postentry annual evaluation
  ---------------------------------------------------------------------------------------------- ------------------ -----------------------------
  Consenting                                                                                     X                   
  Face-to-face interviews                                                                                           
   Sociodemographic information                                                                  X                  X
   Gender transition                                                                             X                   
   Gender affirmation procedures                                                                 X                  X
   Sexual behavior^[a](#tf1){ref-type="table-fn"}^                                               X                  X
   Discrimination^[b](#tf2){ref-type="table-fn"}^ and violence^[c](#tf3){ref-type="table-fn"}^   X                  X
   History of sexually transmitted infections                                                    X                  X
   HIV testing history                                                                           X                  X
   HIV prevention knowledge and risk perception                                                  X                  X
   Substance use                                                                                 X                  X
   ASSIST questionnaire                                                                          X                   
   Depression screening CES-10                                                                   X                   
  Clinical evaluation                                                                                               
   Physical, mental, and medical evaluation                                                      X                  X
   Hormone use                                                                                   X                  X
   HIV care information^[d](#tf4){ref-type="table-fn"}^                                          X                  X
   Antiretroviral use (prevention or treatment)                                                  X                  X
   Medication history                                                                            X                  X
   Anthropometric measurements                                                                   X                  X
  Laboratory testing                                                                                                
   Metabolic panel                                                                               X                  X
   Serum hormone levels                                                                          X                   
   Hematology and chemistry tests                                                                X                  X
   STI testing                                                                                   X                  X
   Counseling and HIV testing^[e](#tf5){ref-type="table-fn"}^                                    X                  X
   HIV drug resistance tests                                                                     X                   
   CD4^+^/CD8^+^ count and plasma HIV RNA^[d](#tf4){ref-type="table-fn"}^                        X                  X
   Stored serum and plasma for future assessments                                                X                  X

Sexual behavior was assessed through questions regarding age of sexual debut, sexual orientation, sex work, practices of receptive and insertive anal sex, vaginal sex, use of condoms, and number of partners.

Discrimination was assessed by the participant\'s perception of being discriminated against in the following settings: at home, school, work, health care, and on the street.

Violence was assessed with questions on sexual and physical violence ever in life and in the past year.

For HIV-infected participants.

For HIV-uninfected participants.

Procedures during visits also included clinical evaluation, as well as morbidity and medication history. We used self-reported information (prior medical diagnosis or use of specific treatment) or current results/measurements to define hypertension, diabetes, and dyslipidemia, as follows: (1) hypertension: average diastolic blood pressure ≥90 mmHg or average systolic blood pressure ≥140 mmHg,^[@B15]^ (2) diabetes: plasma nonfasting glucose ≥200 mg/dL or glycosylated hemoglobin ≥6.5%,^[@B16]^ (3) dyslipidemia: non-HDL-cholesterol ≥160 mg/dL.^[@B17]^ We considered overweight and obesity as body mass index between 25 and 29.9 kg/m^[@B2]^ and ≥30 kg/m^[@B2]^, respectively.

At baseline visit, we performed some additional procedures. We assessed information on gender perception, gender transition, and engagement in sex work. Additionally, participants responded to two validated instruments to assess depression and substance use.^[@B18]^ We screened depression using the 10-item Center for Epidemiologic Studies Depression Scale (CES-D)^[@B19]^ and defined it with a score of ≥10. Problematic substance use was defined when the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) scored moderate or high risk of experiencing health problems and demanding intervention.^[@B22]^

For HIV-infected trans women, clinical information included date of first HIV-positive test, all antiretroviral therapy (ART) used, as well as other concomitant medications, history of non-AIDS-related comorbidities, and AIDS-defining illnesses, classified according to the CDC.^[@B23]^

### Laboratory procedures {#s007}

Procedures during visits also comprised laboratory testing, as described in [Table 1](#T1){ref-type="table"}, including STI testing (syphilis, rectal *Chlamydia trachomatis* and *Neisseria gonorrhea*, hepatitis B and C), and sample storage at all visits for future assessments. For HIV-infected trans women, we measured CD4^+^ and CD8^+^ cells and plasma viral load (VL) during every visit and performed HIV drug resistance test at baseline. For HIV-uninfected trans women who reported condomless anal intercourse in the past 30 days and have a negative HIV rapid test, we also offered pooled HIV RNA testing to identify acute HIV infection.

### Additional data collection {#s008}

We also systematically collected data on hospital admissions (causes and length of stay) and causes of death. For all deaths that occurred, we used a uniform coding system, adapted from the CoDe ("Coding of Death in HIV") method,^[@B24]^ to revise near-death patient information either for the HIV-infected or uninfected participants. The method includes detailed data collection on the causes of death and contributing factors and a centralized review process of the collected data. Information regarding vital status was regularly checked using the patients\' medical charts, via active contact with individuals and family members, and by linkage with the Rio de Janeiro state mortality database, using a previously validated algorithm.^[@B25]^

Study definitions {#s009}
-----------------

### Sociodemographic characteristics {#s010}

We categorized self-reported gender identity as "woman," "transgender woman," "travesti," and "other definitions." "Travesti" is a term used in Brazil that mostly refers to individuals assigned as male at birth and have feminine gender expression, but do not identify as women, and generally do not wish to undergo feminizing vaginoplasty.^[@B5]^ Educational level included four categories, based on the number of years of formal education. Per-person daily income followed the classification of poverty.^[@B26]^ Participants born outside Rio de Janeiro State were classified as internal migrants.

### STI diagnosis {#s011}

We considered active syphilis as a positive treponemal test (rapid immunochromatographic syphilis point-of-care or microhemagglutination assay for *Treponema pallidum*) plus a positive nontreponemal test Venereal Disease Research Laboratory (VDRL) with titers of at least 1/8 at baseline. Active hepatitis B was defined as a positive HB antigen and a negative anti-HB antigen. HCV prevalence was defined as positive anti-HCV.

### Trans-specific characteristics {#s012}

Feminizing procedures included gender-affirming surgeries (breast augmentation, facial feminization, tracheal shave) and sex reassignment surgeries (SRS) (penectomy, orchiectomy, vaginoplasty). We classified the use of feminizing hormonal therapy (FHT) as "never," "current," or "former," according to the report within the last 30 days. As trans women might be using more than one regimen; we inquired on every hormonal medication and classified them as "ethinylestradiol," "intramuscular estradiol plus progestogen," "estradiol plus antiandrogen," or "other." We considered "estradiol plus antiandrogen" as an adequate FHT, according to current guidelines^[@B27]^ and the use of ethinylestradiol or intramuscular progestagen as inadequate, as these substances are not recommended by international guidelines.^[@B27]^ We considered serum testosterone and estradiol levels, respectively, of \<55 ng/dL and between 40 and 199 pg/mL as the target levels for FHT.^[@B31]^

Statistical analysis {#s013}
--------------------

Descriptive characteristics of cohort participants are given as counts, percentages, medians, and interquartile ranges (IQR). We compared baseline characteristics of participants by HIV status using chi-squared test for categorical variables and Kruskal--Wallis test for continuous variables. In addition, we compared clinical and laboratory data for HIV-infected trans women by age strata.

Results {#s014}
=======

As described in [Table 2](#T2){ref-type="table"}, 322 trans women were enrolled from August 2015 to July 2017, of whom 174 (54.0%) were HIV-infected. Median age was 31.5 years (IQR 25.7--39.5). The majority of them self-declared as nonwhite. Overall, participants reported low schooling and income, with 62.0% of them living with below US\$ 10.00 per day. Sexual debut occurred before the age of 10 years for 70.2% of the participants. We observed a high prevalence of physical (*n*=174; 54.0%) and sexual (*n*=149; 46.3%) violence. Out of the 149 participants who reported a history of sexual violence, 95 (63.8%) informed that it occurred the first time before the age of 18 years, and for 58 (38.9%), it occurred before the age of 14 years. The frequency of past engagement in sex work was high (78.6%). Overall, 186 (57.6%) of trans women had a positive treponemal test, and 27.0% had active syphilis at baseline. The prevalence of active rectal *C. trachomatis* and *N. gonorrhea* was 12% and 6%, respectively, and few had active hepatitis B and C. From the 148 HIV-uninfected participants, only 18 (12.2%) were on HIV pre-exposure prophylaxis (PrEP), all of them via participation in a PrEP demonstration study. Hypertension (17.9%) was one of the most common chronic nontransmissible comorbidity. We identified depression in 58% of the participants; depression was significantly higher among the HIV-infected (*p*=0.05).

###### 

Baseline Sociodemographic and Clinical Characteristics of Transgender Women by HIV Serostatus---Transcendendo Cohort, Rio de Janeiro, Brazil, 2015--2017

  Demographics                                                                                                    Total *N*=322 (%)   HIV-uninfected *N*=148 (%)   HIV-infected *N*=174 (%)   *p*-value
  --------------------------------------------------------------------------------------------------------------- ------------------- ---------------------------- -------------------------- -----------
  Age^[a](#tf6){ref-type="table-fn"}^                                                                                                                                                         
   18--24                                                                                                         68 (21.1)           38 (25.7)                    30 (17.2)                  0.128
   25--35                                                                                                         132 (41.0)          63 (42.6)                    69 (39.7)                   
   36--45                                                                                                         73 (22.7)           29 (19.6)                    44 (25.3)                   
   \>45                                                                                                           49 (15.2)           18 (12.2)                    31 (17.8)                   
  Gender identity                                                                                                                                                                             \<0.001
   Woman                                                                                                          74 (23.0)           49 (33.1)                    25 (14.4)                   
   Transgender woman                                                                                              112 (34.8)          53 (35.8)                    59 (33.9)                   
   Travesti                                                                                                       128 (39.8)          43 (29.1)                    85 (48.9)                   
   Other definitions                                                                                              8 (2.5)             3 (2.0)                      5 (2.9)                     
  Self-declared race/color                                                                                                                                                                    0.111
   White                                                                                                          80 (24.8)           39 (26.4)                    41 (23.6)                   
   Black                                                                                                          73 (22.7)           26 (17.6)                    47 (27.0)                   
   Mixed                                                                                                          161 (50.0)          81 (54.7)                    80 (46.0)                   
   Other                                                                                                          8 (2.5)             2 (1.4)                      6 (3.4)                     
  Years of education^[a](#tf6){ref-type="table-fn"}^                                                                                                                                          0.023
   \<4                                                                                                            19 (5.9)            5 (3.4)                      14 (8.0)                    
   4--8                                                                                                           100 (31.1)          39 (26.4)                    61 (35.1)                   
   9--12                                                                                                          177 (55.0)          87 (58.8)                    90 (51.7)                   
   \>12                                                                                                           26 (8.1)            17 (11.5)                    9 (5.2)                     
  Income (in US\$/day)^[a](#tf6){ref-type="table-fn"},[b](#tf7){ref-type="table-fn"}^                                                                                                         \<0.001
   \>10.00                                                                                                        55 (17.1)           34 (23.0)                    21 (12.1)                   
   1.91--10.00                                                                                                    161 (50.0)          85 (56.1)                    78 (44.8)                   
   ≤1.90                                                                                                          39 (12.1)           19 (12.8)                    20 (11.5)                   
   Missing                                                                                                        67 (20.8)           12 (8.1)                     55 (31.6)                   
  Internal migrants^[c](#tf8){ref-type="table-fn"}^                                                               87 (27.0)           45 (30.4)                    42 (24.1)                  0.256
  Age at sexual debut^[a](#tf6){ref-type="table-fn"}^                                                                                                                                         0.757
   \<10                                                                                                           226 (70.2)          100 (67.6)                   126 (72.4)                  
   10--13                                                                                                         23 (7.1)            12 (8.1)                     11 (6.3)                    
   14--17                                                                                                         7 (2.2)             4 (2.7)                      3 (1.7)                     
   ≥18                                                                                                            66 (20.5)           32 (21.6)                    34 (19.5)                   
  Ever suffered physical violence                                                                                 174 (54.0)          74 (50.0)                    100 (57.5)                 0.219
  Ever suffered sexual violence (rape)                                                                            149 (46.3)          66 (44.6)                    83 (47.7)                  0.656
  Engagement in sex work                                                                                                                                                                      0.002
   Never                                                                                                          69 (21.4)           44 (29.7)                    25 (14.4)                   
   Current                                                                                                        150 (46.6)          58 (39.2)                    92 (52.9)                   
   Past                                                                                                           103 (32.0)          46 (31.1)                    57 (32.8)                   
  Current syphilis                                                                                                                                                                            
   No                                                                                                             184 (57.1)          106 (71.6)                   78 (44.8)                  \< 0.001
   Yes                                                                                                            88 (27.3)           35 (23.6)                    53 (30.5)                   
   Missing                                                                                                        50 (15.5)           7 (4.7)                      43 (24.7)                   
  Rectal chlamydia                                                                                                                                                                            0.004
   No                                                                                                             241 (74.8)          121 (81.8)                   120 (69.0)                  
   Yes                                                                                                            40 (12.4)           18 (12.2)                    22 (12.6)                   
   Missing                                                                                                        41 (12.7)           9 (6.1)                      32 (18.4)                   
  Rectal gonorrhea                                                                                                                                                                            0.002
   No                                                                                                             263 (81.7)          132 (89.2)                   131 (75.3)                  
   Yes                                                                                                            19 (5.9)            8 (5.4)                      11 (6.3)                    
   Missing                                                                                                        40 (12.4)           8 (5.4)                      32 (18.4)                   
  Hepatitis B                                                                                                                                                                                 \< 0.001
   No                                                                                                             268 (83.2)          140 (94.6)                   128 (73.6)                  
   Yes                                                                                                            9 (2.8)             1 (0.7)                      8 (4.6)                     
   Missing                                                                                                        45 (14.0)           7 (4.7)                      38 (21.8)                   
  Hepatitis C                                                                                                                                                                                 0.157
   No                                                                                                             307 (95.3)          145 (98.0)                   162 (93.1)                  
   Yes                                                                                                            11 (3.4)            2 (1.4)                      9 (5.2)                     
   Missing                                                                                                        4 (1.2)             1 (0.7)                      3 (1.7)                     
  Diabetes mellitus                                                                                               7 (2.2)             2 (1.4)                      5 (2.9)                    0.459
  Dyslipidemia                                                                                                    24 (7.5)            8 (5.4)                      16 (9.2)                   0.281
  Systemic arterial hypertension                                                                                  54 (17.9)           26 (18.3)                    28 (17.6)                  0.994
  Obesity/overweight                                                                                                                                                                          
   No                                                                                                             170 (52.8)          73 (49.3)                    97 (55.7)                   
   Yes                                                                                                            138 (42.9)          73 (49.3)                    65 (37.4)                  0.011
   Missing                                                                                                        14 (4.3)            2 (1.4)                      12 (6.9)                    
  Depression^[d](#tf9){ref-type="table-fn"}^                                                                      186 (57.8)          77 (52.0)                    109 (62.6)                 0.054
  Problematic use of substances (ASSIST score^[d](#tf9){ref-type="table-fn"}^)^[e](#tf10){ref-type="table-fn"}^                                                                               
   Alcohol                                                                                                        55 (21.5)           18 (16.4)                    37 (25.3)                  0.115
   Tobacco                                                                                                        145 (56.6)          54 (49.1)                    91 (62.3)                  0.047
   Cannabis                                                                                                       74 (28.9)           22 (20.0)                    52 (35.6)                  0.010
   Cocaine                                                                                                        61 (23.8)           15 (13.6)                    46 (31.5)                  0.002
   Amphetamine stimulants                                                                                         7 (2.7)             2 (1.8)                      5 (3.4)                    0.702

Continuous variables were reclassified as categorical.

US\$1.00=R\$3.85.

Participants born outside Rio de Janeiro state were classified as internal migrants.

Screening by CES-D10.

ASSIST score of 11+ for alcohol and 4+ for other substances.

ASSIST, Alcohol, Smoking and Substance Involvement Screening Test.

Compared to those HIV-uninfected, HIV-infected trans women had lower schooling and income, reported more engagement in sex work, and had higher rates of STIs. HIV-uninfected and HIV-infected trans women significantly differed in gender identity, as HIV-uninfected trans women more frequently self-reported as women (33.1% vs. 14.4%) and less frequently as travestis (29.1% vs. 48.8%) and had higher obesity/overweight prevalence ([Table 2](#T2){ref-type="table"}).

A high number of trans women reported problematic use of tobacco (56.6%), cannabis (28.9%), cocaine (23.8%), and alcohol (21.5%) ([Table 2](#T2){ref-type="table"}). Compared to those HIV-uninfected, higher proportions of HIV-infected trans women had problematic use of cannabis, cocaine, and tobacco.

The majority of trans women perceived themselves as transgender during childhood (63.7% aged ≤10), and the median age of gender transition was 16 years (IQR 14--18) ([Table 3](#T3){ref-type="table"}). Any feminizing procedure was reported by 41.0%, with only 5.9% reporting SRS. SRS was more frequent among HIV-uninfected than in HIV-infected trans women. About a third had gender-affirming surgery, and 49.1% reported prior industrial silicone filler injection. Most trans women have used hormones at some point, and around half (49.1%) were on current FHT, mostly nonprescribed by health professionals (78.7%). Fewer HIV-infected trans women were currently using hormones (both prescribed and nonprescribed) compared with HIV-uninfected trans women (40.2% vs. 59.5%; *p*\<0.001). Among trans women currently using hormones (*N*=158), most of them were using inadequate FHT (57.6% were using intramuscular estradiol plus progestagen, 37.3% reported current use of ethinylestradiol). Only 13.9% reported the use of an adequate regimen (estradiol plus antiandrogen) and 9.5% were under current medical-guided hormonal use. Among trans women currently on hormones, 56.3% and 29.7% achieved the target testosterone and estradiol levels, respectively; 16.5% had estradiol levels higher than recommended.

###### 

Transitioning Characteristics of Transgender Women According to HIV Serostatus---Transcendendo Cohort, Rio de Janeiro, Brazil, 2015--2017

  Transitioning characteristics                                                         Total *N*=322   HIV-uninfected *N*=148   HIV-infected *N*=174   *p*
  ------------------------------------------------------------------------------------- --------------- ------------------------ ---------------------- ---------
  Age of gender perception^[a](#tf12){ref-type="table-fn"}^                                                                                             
   ≤7                                                                                   112 (34.8)      56 (37.8)                56 (32.2)              0.254
   8--10                                                                                93 (28.9)       39 (26.4)                54 (31.0)               
   11--13                                                                               66 (20.5)       29 (19.6)                37 (21.3)               
   ≥14                                                                                  47 (14.6)       24 (16.2)                23 (13.2)               
   Missing                                                                              4 (1.2)         0 (0.0)                  4 (2.3)                 
  Age of gender transition^[a](#tf12){ref-type="table-fn"}^                                                                                             
   \<14                                                                                 59 (18.3)       24 (16.2)                35 (20.1)              0.151
   14--17                                                                               148 (46.0)      63 (42.6)                85 (48.9)               
   ≥18                                                                                  114 (35.4)      61 (41.2)                53 (30.5)               
   Missing                                                                              1 (0.3)         0 (0.0)                  1 (0.6)                 
  Ever performed gender affirmation procedures^[b](#tf13){ref-type="table-fn"}^         132 (41.0)      59 (39.9)                73 (42.0)              0.790
  Ever had sex reassignment surgery^[b](#tf13){ref-type="table-fn"}^                    19 (5.9)        15 (10.1)                4 (2.3)                0.006
  Ever injected fillers                                                                 158 (49.1)      57 (38.5)                101 (58.0)             \<0.001
  Hormone use                                                                                                                                           
   Current                                                                              158 (49.1)      88 (59.5)                70 (40.2)              0.002
   Past                                                                                 147 (45.7)      52 (35.1)                95 (54.6)               
   Never                                                                                16 (5.0)        8 (5.4)                  8 (4.6)                 
   Missing                                                                              1 (0.3)         0 (0.0)                  1 (0.6)                 
  Medically guided hormone use                                                                                                                          0.014
   Never                                                                                240 (78.7)      100 (71.4)               140 (84.8)              
   Current                                                                              29 (9.5)        21 (15.0)                8 (4.8)                 
   Past                                                                                 19 (6.2)        10 (7.1)                 9 (5.5)                 
   Missing                                                                              17 (5.6)        9 (6.4)                  8 (4.8)                 
  Current use of ethinylestradiol^[c](#tf14){ref-type="table-fn"}^                      59 (37.3)       35 (39.8)                24 (34.3)              0.587
  Current use of IM estradiol plus progestagen^[c](#tf14){ref-type="table-fn"}^         91 (57.6)       45 (51.1)                46 (65.7)              0.093
  Current use of estradiol plus antiandrogen^[c](#tf14){ref-type="table-fn"}^           22 (13.9)       16 (18.2)                6 (8.6)                0.133
  Total testosterone^[a](#tf12){ref-type="table-fn"},[c](#tf14){ref-type="table-fn"}^                                                                   
   At target level                                                                      89 (56.3)       53 (60.2)                36 (51.4)              0.221
   Above target level                                                                   64 (40.5)       34 (38.6)                30 (42.9)               
   Missing                                                                              5 (3.2)         1 (1.1)                  4 (5.7)                 
  Estradiol^[a](#tf12){ref-type="table-fn"},[c](#tf14){ref-type="table-fn"}^                                                                            
   Below target level                                                                   80 (50.6)       47 (53.4)                33 (47.1)              0.433
   At target level                                                                      47 (29.7)       26 (29.5)                21 (30.0)               
   Above target level                                                                   26 (16.5)       14 (15.9)                12 (17.1)               
   Missing                                                                              5 (3.2)         1 (1.1)                  4 (5.7)                 

Continuous variables were reclassified as categorical.

Breast augmentation, facial feminization, tracheal shave, or sex reassignment surgery (vaginoplasty, penectomy, and oorchiectomy).

Evaluated to trans women currently using hormones (*n*=158).

IM, intramuscular.

Among HIV-infected trans women, median time since HIV diagnosis was 1.8 years (IQR 0--7.3); the median CD4^+^ count was 582 cells/mm^[@B3]^ (IQR 372--800); and 60% of them were using ART. Out of the 70 HIV-infected trans women who were not on ART, 38.6% (27) had been diagnosed with HIV on the same day of Transcendendo enrollment, 57.1% (40) had already been diagnosed with HIV but had never used ART, and 4.3% (3) had been on ART before but were not currently using it. Among those currently using ART, 67.3% had undetectable VL ([Table 4](#T4){ref-type="table"}). ART use was less frequent among younger HIV-infected trans women, but among those who used ART, they were more likely to have undetectable VL: 80.0% among those aged 18--24 versus 57.1% among those aged ≥46. Forty (23.0%) HIV-infected trans women reported a previous AIDS-defining illness; 16.7% reported previous tuberculosis.

###### 

Clinical Characteristics of HIV-Infected Transgender Women, According to Age---Transcendendo Cohort, Rio de Janeiro, Brazil, 2015--2017

  Clinical characteristics                                                            Total *N*=174 (%)   18--24 *N*=30 (%)   25--35 *N*=69 (%)   36--45 *N*=44 (%)   46+*N*=31 (%)   *p*
  ----------------------------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- --------------- ---------
  Mode of HIV acquisition                                                                                                                                                             
   Sex with men                                                                       161 (92.5)          27 (90.0)           66 (95.7)           43 (97.7)           25 (80.6)       0.042
   IDU                                                                                2 (1.1)             0 (0.0)             0 (0.0)             0 (0.0)             2 (6.5)          
   Other/unknown                                                                      11 (6.5)            3 (10.0)            3 (4.3)             1 (2.3)             4 (12.9)         
  Current CD4 count (cells/mm^3^)^[a](#tf16){ref-type="table-fn"}^                                                                                                                    
   \<250                                                                              21 (12.1)           2 (6.7)             11 (15.9)           4 (9.1)             4 (12.9)        0.884
   251--500                                                                           36 (20.7)           6 (20.0)            15 (21.7)           9 (20.5)            6 (19.4)         
   \>500                                                                              84 (48.3)           16 (53.3)           29 (42.0)           25 (56.8)           14 (45.2)        
   Missing                                                                            33 (19.0)           6 (20.0)            14 (20.3)           6 (13.6)            7 (22.6)         
  Currently on ART                                                                                                                                                                    
   No                                                                                 70 (40.2)           25 (83.3)           36 (52.2)           6 (13.6)            3 (9.7)         \<0.001
   Yes                                                                                104 (59.8)          5 (16.7)            33 (47.8)           38 (86.4)           28 (90.3)        
  Current HIV RNA viral load (copies/mL) (*N*=103)^[b](#tf17){ref-type="table-fn"}^                                                                                                   
   \<40                                                                               70 (67.3)           4 (80.0)            23 (69.7)           27 (71.1)           16 (57.1)       0.775
   ≥40                                                                                22 (21.2)           1 (20.0)            5 (15.2)            8 (21.1)            8 (28.6)         
   Missing                                                                            12 (11.5)           0 (0.0)             5 (15.2)            3 (7.9)             4 (14.3)         
  Had previous AIDS-defining illness                                                  40 (23.0)           2 (6.7)             8 (11.6)            17 (38.6)           13 (41.9)       \<0.001
  Had previous TB^[c](#tf18){ref-type="table-fn"}^                                    29 (16.7)           2 (6.7)             11 (15.9)           11 (25.0)           10 (32.3)       0.051

Continuous variables were reclassified as categorical.

Calculated only for those on ART.

After HIV diagnosis.

ART, antiretroviral therapy; IDU, injection drug use.

Discussion {#s015}
==========

Our study presents baseline characteristics of the Transcendendo cohort. Our findings reinforce trans women as a disadvantaged and disenfranchised group, with multiple needs that go beyond health itself. Trans women bear a disproportionate burden of adverse outcomes that are sparingly evaluated, mostly by cross-sectional studies.^[@B2]^ Although transgender populations face adverse experiences worldwide, the context of marginalization and social exclusion may be even worse in a low- or middle-income country (LMIC), with poor access to hormone use supervision, gender-related interventions, HIV prevention and care, and support for problematic substance use. Transcendendo is the first Latin-American cohort to evaluate the social, demographic, and clinical aspects of HIV-infected and HIV-uninfected trans women.

Sociodemographic context of exclusion, discrimination, and violence {#s016}
-------------------------------------------------------------------

Our results reveal that the participants of Transcendendo have low education level and income, experience high physical and sexual violence rates, and frequently engage in sex work. These unfavorable conditions are in accordance with other authors.^[@B32]^ The social context that trans women face is a combination of diverse related factors such as exclusion, stigma, violence, lack of justice, and poor access to education and employment, which usually exacerbate one another and increase vulnerability to HIV and other diseases.^[@B36]^ Although Brazilian laws protect transgender rights, transphobia is ingrained diffusely, and Brazil is the leading country of homicides of transgender people, accounting for almost 40% of all reported murders of transgender people worldwide.^[@B37]^

Mental and physical health {#s017}
--------------------------

We found that depression was very common in our cohort (58%), comparable to those described using similar screening scales (prevalence between 44% and 49%)^[@B14],[@B38],[@B39]^ and more prevalent than observed in the cisgender Brazilian population (13.2--20.2%).^[@B40],[@B41]^ This finding is in accordance with data from Canada and the United States, which observed a higher prevalence of depression among trans women compared to cisgender population.^[@B14],[@B42]^ The factors associated with gender minority stress, such as victimization, rejection, discrimination, and nonaffirmation of gender identity, seem to be associated with depression and other mental health conditions.^[@B43],[@B44]^ We found a lower prevalence of hypertension compared to the data from the general population of Brazil,^[@B45]^ which may be due to the lower age of our sample. Additionally, diabetes and dyslipidemia were less frequent in our population, compared with other general population studies in Brazil^[@B46],[@B47]^ and with the Canadian trans women cohort.^[@B14]^ These contrasts may again be related to the demographic characteristics of the populations, such as age and gender, as well as to the differences in definitions adopted by each study.

Trans-specific interventions {#s018}
----------------------------

Most trans women used hormones at some point, almost always nonprescribed by health professionals, at higher levels than described in the United States.^[@B48]^ We also identified alarming rates of industrial silicon filler injection and lower rates of SRS than described in other countries.^[@B52],[@B53]^ These differences might reflect worse access to general and transgender-specific health care. Gender-affirming hormone therapy is the main intervention sought by transgender people, since it allows the development of characteristics compatible with their gender identity.^[@B28]^ FHT is considered safe under medical supervision,^[@B54]^ but nonprescribed hormones are associated with the uptake of inadequate compounds, improper dosing, and lack of monitoring.^[@B48]^ In our cohort, most trans women did not achieve the recommended levels of hormones; more than a third was using ethinylestradiol (37.3%) and some had higher estradiol levels than recommended. Ethinylestradiol is not recommended to feminization due to its high thrombogenic risk.^[@B54]^ The combination of intramuscular estradiol plus progestagen, commonly used in our setting, is understudied, but might be associated with cardiovascular disease and breast cancer in postmenopausal women.^[@B55]^ In summary, the high rates of inadequate use of hormones in our sample is alarming and points to the unmet needs of this underprivileged group.

HIV infection {#s019}
-------------

Compared with those HIV-uninfected, HIV-infected trans women had lower educational levels, were involved in more sex work, and reported problematic use of some substances. Forty percent were not on ART, especially the younger population with two-thirds of those on ART having an undetectable VL. These results highlight the need for better retention in care, which will ultimately impact HIV transmission. HIV epidemic among trans women is considered a syndemic condition, which generally develops in the context of social disadvantage and inequality.^[@B4]^ It has been suggested that syndemics may also explain the difficulties in the treatment of HIV infection apart from other coexisting social, behavioral, and medical conditions that limit successful and sustained engagement in health care.^[@B12]^

Strengths and limitations {#s020}
-------------------------

The main strengths of this study are the unique evaluation of an extremely marginalized and vulnerable population, the use of a standardized data collection platform, and the systematic medical and laboratory assessments. Very few studies have evaluated trans women longitudinally, none in LMICs. In addition, trans women are a hard-to-reach and hard-to-retain population for health care.^[@B56]^ So, to improve retention and outcome assessment, we established a welcoming, gender-affirming setting, which facilitated the engagement and retention of trans women. Also, we established a linkage with the state-level mortality database to improve lost to follow-up evaluation in our population, since it can help identify deaths not reported to our study team. Our study also has some limitations. Foremost, Transcendendo is an open cohort restricted to a convenience sample from the Rio de Janeiro population, and therefore the findings cannot be generalizable to the whole trans women population. Also, as this is a clinic-based cohort, procedures are linked to medical care, which may lead to some missing data. However, to minimize these occurrences, our study procedures are carried out annually.

Conclusions {#s021}
===========

Transcendendo is a unique opportunity to longitudinally assess transgender health outcomes among young trans women from a LMIC, including issues regarding hormone and antiretroviral use, incident comorbidities, and complications such as metabolic and cardiovascular events. Baseline results contribute to bridging the gaps concerning transgender people\'s health and reinforce that transgender care cannot be disentangled from the social environment that surrounds trans women. HIV infection is a major concern among trans women, but transgender members claim that their marginalization needs to be addressed as the highest priority to succeed in a response to HIV.^[@B36]^ Transcendendo results may guide future research and trans-specific interventions by addressing transgender vulnerabilities and needs and supporting the development of strategies to diminish stigma, improve health care environment, guide future research on trans morbidities, substance use, feminizing hormone therapy, and trans-specific interventions to support health-related recommendations.
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ART

:   antiretroviral therapy

ASSIST

:   Alcohol, Smoking and Substance Involvement Screening Test

FHT

:   feminizing hormonal therapy

IDU

:   injection drug use

IM

:   intramuscular

IQR

:   interquartile range

LMIC

:   low- or middle-income country

RDS

:   respondent-driven sampling

SRS

:   sex reassignment surgeries

STI

:   sexually transmitted infection
